RxDoctor Payments Data

Thomas Schneider, MD

Pulmonary Disease · Jefferson City, MONPI 1003875360

Payments from drug & device makers

$15,211in general payments, 2019–2025

Across 999 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • AbbVie$979
  • Regeneron Healthcare Solutions, Inc.$779
  • Pfizer$757
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$15,196100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,211 in reported general payments places this provider in the 75th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$550,707
Medicare patients
710
Services billed
12,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban410$344,291
Trelegy ElliptaFluticasone/Umeclidin/Vilanter261$239,358
Breztri AerosphereBudesonide/Glycopyr/Formoterol267$207,121
OzempicSemaglutide157$169,654
Breo ElliptaFluticasone/Vilanterol109$63,997
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$43,618
XareltoRivaroxaban50$39,814
JanuviaSitagliptin Phosphate26$39,020
JardianceEmpagliflozin38$37,899
Combivent RespimatIpratropium/Albuterol Sulfate58$35,939
MounjaroTirzepatide18$27,660
SymbicortBudesonide/Formoterol Fumarate80$23,729
ProliaDenosumab13$20,529
Tresiba Flextouch U-200Insulin Degludec19$15,688
FarxigaDapagliflozin Propanediol12$14,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy$1,682$360,969474 claims
PfizerEliquis, Abrysvo$757$354,251444 claims
AstraZenecaBreztri Aerosphere, Symbicort, Farxiga$3,490$245,598359 claims
Novo NordiskOzempic, Rybelsus$572$183,902169 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$1,131$86,269113 claims
MerckJanuvia, Dulera$441$47,85351 claims
Johnson & JohnsonXarelto$94$39,81450 claims
Lilly USA, LLCMounjaro$77$27,66018 claims
AmgenProlia$295$20,52913 claims
Sumitomo Pharma America, Inc.Gemtesa$142$13,05727 claims
AbbVieLinzess$979$12,50020 claims
Astellas Pharma US IncMyrbetriq$14$11,36911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Jefferson City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →